English 简体中文
Professional talent from China and the United States jointly push  the progress and effectiveness of drug research and development.

We have strong experience and successes in target mechanism research, target selection, peptide design and synthesis, nuclear medicine clinical trials, etc., which provide the right strategy and direction for new drug research and development.

We have dedicated and hard-work team working on radiochemistry, radiobiology, peptide chemistry, metallodrugs CMC, clinical operations, etc., ensure the efficient development and implementation of drug R&D work.

Multiple innovative and generic drugs have been approved and commercialized by our development teams.

The development teams have successful experience in entrepreneurship, drug launches and corporate management

Targeted molecules are coupled with cytotoxins to reduce the limitation of radionuclide therapy in the treatment of a variety of solid tumors.

Targets such as FAP and PSMA are combined with other therapeutic targets to treat a variety of solid tumors.

VitsGen started with PSMA and FAP targets to create best-in-class and first-in-class cancer diagnostic and therapeutic solutions, and by continuous innovation, Vitsgen aims to develop more first-in-class theranostic solutions for unmet medical needs.

PSMA, FAP and other tumor overexpression targets are used in combination with radiolabeled therapy to treat various advanced malignant tumors, and new targets are being development continuously.